Pyrazolam
Benzodiazepine
- AU: S4[1]
- CA: Schedule IV
- DE: NpSG (Industrial and scientific use only)
- UK: Class C
- US: Unscheduled
- 8-Bromo-1-methyl-6-(pyridin-2-yl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
- 39243-02-2
- 12562545
- 15417688
- 8LH16383PK
- ChEMBL3246831
- Interactive image
- CC1=NN=C2CN=C(C3=NC=CC=C3)C3=CC(Br)=CC=C3N12
InChI
- InChI=1S/C16H12BrN5/c1-10-20-21-15-9-19-16(13-4-2-3-7-18-13)12-8-11(17)5-6-14(12)22(10)15/h2-8H,9H2,1H3
- Key:BGRWSFIQQPVEML-UHFFFAOYSA-N
Pyrazolam (SH-I-04)[2] is a benzodiazepine derivative originally developed by a team led by Leo Sternbach at Hoffman-La Roche in the 1970s.[3] It has since been "rediscovered" and sold as a designer drug since 2012.[4][5][6][7][8][9][excessive citations]
Pyrazolam has structural similarities to alprazolam[10] and bromazepam. Unlike other benzodiazepines, pyrazolam does not appear to undergo metabolism, instead being excreted unchanged in the urine.[4]
Legal status
United Kingdom
In the UK, pyrazolam has been classified as a Class C drug by section 5 of the May 2017 amendment to The Misuse of Drugs Act 1971 along with several other designer benzodiazepine drugs.[11]
See also
References
- ^ (customs (prohibited imports) regulations 1956 - schedule 4, 1956)
- ^ Clayton T, Poe MM, Rallapalli S, Biawat P, Savić MM, Rowlett JK, et al. (2015). "A Review of the Updated Pharmacophore for the Alpha 5 GABA(A) Benzodiazepine Receptor Model". International Journal of Medicinal Chemistry. 2015: 430248. doi:10.1155/2015/430248. PMC 4657098. PMID 26682068.
- ^ US 3954728, Sternbach LH, Walser A, "Preparation of triazolo benzodiazepines and novel compounds", issued 4 May 1976, assigned to Hoffmann La Roche Inc.
- ^ a b Moosmann B, Hutter M, Huppertz LM, Ferlaino S, Redlingshöfer L, Auwärter V (July 2013). "Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine". Forensic Toxicology. 31 (2): 263–271. doi:10.1007/s11419-013-0187-4. S2CID 23273522.
- ^ Moosmann B, King LA, Auwärter V (June 2015). "Designer benzodiazepines: A new challenge". World Psychiatry. 14 (2): 248. doi:10.1002/wps.20236. PMC 4471986. PMID 26043347.
- ^ Pettersson Bergstrand M, Helander A, Hansson T, Beck O (April 2017). "Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays". Drug Testing and Analysis. 9 (4): 640–645. doi:10.1002/dta.2003. PMID 27366870.
- ^ Høiseth G, Tuv SS, Karinen R (November 2016). "Blood concentrations of new designer benzodiazepines in forensic cases". Forensic Science International. 268: 35–38. doi:10.1016/j.forsciint.2016.09.006. PMID 27685473.
- ^ Manchester KR, Maskell PD, Waters L (March 2018). "Experimental versus theoretical log D7.4 , pKa and plasma protein binding values for benzodiazepines appearing as new psychoactive substances". Drug Testing and Analysis. 10 (8): 1258–1269. doi:10.1002/dta.2387. PMID 29582576.
- ^ Manchester KR, Waters L, Haider S, Maskell PD (July 2022). "The blood-to-plasma ratio and predicted GABAA-binding affinity of designer benzodiazepines". Forensic Toxicology. 40 (2): 349–356. doi:10.1007/s11419-022-00616-y. PMC 9715504. PMID 36454409. S2CID 247455284.
- ^ Hester JB, Rudzik AD, Kamdar BV (November 1971). "6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines which have central nervous system depressant activity". Journal of Medicinal Chemistry. 14 (11): 1078–1081. doi:10.1021/jm00293a015. PMID 5165540.
- ^ "The Misuse of Drugs Act 1971 (Amendment) Order 2017". legislation.gov.uk.
- v
- t
- e
- 2-Oxoquazepam
- 3-Hydroxyphenazepam
- Bromazepam
- BMS-906024*
- Camazepam
- Carburazepam
- Chlordiazepoxide
- Cinazepam
- Cinolazepam
- Clonazepam
- Cloniprazepam
- Clorazepate
- Cyprazepam
- Delorazepam
- Demoxepam
- Desmethylflunitrazepam
- Devazepide*
- Diazepam
- Diclazepam
- Difludiazepam
- Doxefazepam
- Elfazepam
- Ethyl carfluzepate
- Ethyl dirazepate
- Ethyl loflazepate
- Flubromazepam
- Fletazepam
- Fludiazepam
- Flunitrazepam
- Flurazepam
- Flutemazepam
- Flutoprazepam
- Fosazepam
- Gidazepam
- Halazepam
- Iclazepam
- Irazepine*
- Kenazepine
- Ketazolam
- Lorazepam
- Lormetazepam
- Lufuradom*
- Meclonazepam
- Medazepam
- Menitrazepam
- Metaclazepam
- Motrazepam
- N-Desalkylflurazepam
- Nifoxipam
- Nimetazepam
- Nitemazepam
- Nitrazepam
- Nitrazepate
- Nordazepam
- Nortetrazepam
- Oxazepam
- Phenazepam
- Pinazepam
- Pivoxazepam
- Prazepam
- Proflazepam
- Quazepam
- QH-II-66
- Reclazepam
- RO4491533*
- Ro05-4082
- Ro5-4864*
- Ro07-5220
- Ro07-9749
- Ro20-8065
- Ro20-8552
- SH-I-048A
- Sulazepam
- Temazepam
- Tetrazepam
- Tifluadom*
- Timelotem*
- Tolufazepam
- Triflunordazepam
- Tuclazepam
- Uldazepam
- Adinazolam
- Alprazolam
- Balovaptan*
- Bromazolam
- Clonazolam
- Estazolam
- Fluadinazolam
- Flualprazolam
- Flubromazolam
- Flunitrazolam
- Nitrazolam
- Phenazolam
- Pyrazolam
- Rilmazolam (active metabolite of Rilmazafone)
- Triazolam
* atypical activity profile (not GABAA receptor ligands)